[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

CHICAGO , May 29, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 1/1b CHRYSALIS-2 study evaluating intravenous RYBREVANT ® (amivantamab-vmjw)...

JNJ : 225.33 (-2.37%)
Unusual Options Activity Points to Boston Scientific Stock as a Hot M&A Target

Boston Scientific posted two of the top three Volume-to-Open Interest ratios during Thursday's trading session, a notable signal often associated with heightened market speculation. This unusual options...

BSX : 48.31 (-1.63%)
JNJ : 225.33 (-2.37%)
AbbVie Stock: Is ABBV Outperforming the Healthcare Sector?

AbbVie has underperformed the healthcare sector, and analysts remain somewhat optimistic about the stock’s outlook.

XLV : 149.47 (-0.93%)
JNJ : 225.33 (-2.37%)
ABBV : 217.72 (-0.42%)
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

CHICAGO , May 29, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically...

JNJ : 225.33 (-2.37%)
FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

TREMFYA ® showed significant inhibition of structural joint damage in adults with active psoriatic arthritis

JNJ : 225.33 (-2.37%)
3 Dividend Kings to Buy Now to Replace the Social Security Income You're About to Lose

The Congressional Budget Office (CBO) released a report this year containing one number that should change how every American near retirement thinks about income. Here's 3 dividend stocks to replace that...

KO : 79.01 (-1.74%)
PG : 143.56 (-1.61%)
JNJ : 225.33 (-2.37%)
Is Eli Lilly Stock Outperforming the Nasdaq?

Eli Lilly has outpaced the Nasdaq Composite over the past year, and analysts remain very confident in its longer-term trajectory.

$NASX : 26,972.62 (+0.20%)
JNJ : 225.33 (-2.37%)
LLY : 110.50 (-90.19%)
Is Johnson & Johnson Stock Outperforming the Dow?

Johnson & Johnson has outperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.

JNJ : 225.33 (-2.37%)
LLY : 110.50 (-90.19%)
$DOWI : 51,032.46 (+0.72%)
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15 th to review second-quarter...

JNJ : 225.33 (-2.37%)
3 Vanguard Dividend Funds for Low-Cost Income

Dividend funds help you diversify while collecting equity income. You can keep more of that income thanks to the low fees on these Vanguard dividend funds.

AAPL : 312.06 (-0.14%)
AVGO : 446.77 (+4.73%)
VHYAX : 47.99 (+0.50%)
JPM : 299.31 (+0.87%)
JNJ : 225.33 (-2.37%)
VYM : 159.19 (+0.55%)
NSRGY : 101.4400 (-0.49%)
HSBC : 93.74 (+0.85%)
VIHAX : 48.49 (+0.19%)
VIG : 234.65 (+0.33%)
XOM : 145.26 (-1.16%)
VYMI : 100.02 (-0.03%)

Barchart Exclusives

Visa vs. Mastercard Stock: Using Barchart Data to Pick the Best Payments Giant Now
Visa and Mastercard dominate in payments, but one's stronger financials and dividend growth give it a slight edge. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.